Vanda Pharmaceuticals Inc. Common Stock VNDA
i
Market dataready · fetched 2026-11-12T17:14:00.747Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T17:12:47.058268461Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T17:14:00.233409+00:00
Vanda Pharmaceuticals Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 3.21 | 349.9% | 30.8% | |||
| 30Δ | 7.16 | 439.8% | 85.0% | 3.45 | 306.1% | 25.4% |
| 35Δ | 5.92 | 349.0% | 54.5% | 3.69 | 262.2% | 19.9% |
| 40Δ | 3.93 | 218.3% | 14.5% | |||
| 45Δ | ||||||
| 50Δ | ||||||
| 55Δ | ||||||
| 60Δ | 3.86 | 131.6% | 4.8% | |||
| 65Δ | 3.46 | 223.5% | 4.6% | |||
| 70Δ | 3.07 | 315.4% | 4.3% | |||
| 75Δ | 2.67 | 407.3% | 4.1% | |||
| 80Δ | 2.28 | 499.2% | 3.9% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.21
- IV
- 349.9%
- B/E move
- 30.8%
30Δ
- Pseudo strike
- 7.16
- IV
- 439.8%
- B/E move
- 85.0%
- Pseudo strike
- 3.45
- IV
- 306.1%
- B/E move
- 25.4%
35Δ
- Pseudo strike
- 5.92
- IV
- 349.0%
- B/E move
- 54.5%
- Pseudo strike
- 3.69
- IV
- 262.2%
- B/E move
- 19.9%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.93
- IV
- 218.3%
- B/E move
- 14.5%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 3.86
- IV
- 131.6%
- B/E move
- 4.8%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 3.46
- IV
- 223.5%
- B/E move
- 4.6%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 3.07
- IV
- 315.4%
- B/E move
- 4.3%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 2.67
- IV
- 407.3%
- B/E move
- 4.1%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 2.28
- IV
- 499.2%
- B/E move
- 3.9%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 157.95% | |
| 101.97% | |
| 109.09% | |
| 124.25% | |
| 108.73% | |
| 105.84% | |
| 106.37% | |
| 159.66% | |
| 115.13% |
Biotechnology
VOR
Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. The company is headquartered in…
More →VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. The company is headquartered in Boulder, Colorado.
More →VRTX
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
More →VSTM
Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. The company is headquartered in…
More →VYGR
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, is focused on developing treatments for patients with severe neurological diseases. The company is headquartered…
More →WHWK
Description unavailable
More →